PROTEUS Revolutionizes Drug Discovery, Modella AI & AstraZeneca Team Up, Viome & Microsoft Enhance Health AI - Life AI Weekly #24

Hi there,

In this edition of Life AI Weekly, we delve into the latest advancements in healthcare and life sciences AI. University of Sydney has developed PROTEUS, a tool designed to aid in molecule evolution, potentially revolutionizing drug discovery processes. Meanwhile, Modella AI has partnered with AstraZeneca to drive AI-driven cancer clinical development, marking a significant step forward in the fight against cancer.

Additionally, Veeda Lifesciences has teamed up with Mango Sciences to integrate AI into clinical trials, aiming to enhance efficiency and accuracy. In the realm of health analysis, Viome is collaborating with Microsoft to boost AI capabilities, promising more precise health assessments. Stay tuned as we explore these stories and more in the world of AI-driven healthcare innovations.

Synfini Inc., a California-based startup, has secured $8.9 million in funding to advance its AI-driven drug discovery platform, bringing its total funding to $53 million. In the first half of 2025, digital health funding reached $6.4 billion, with AI-enabled startups capturing a significant portion of the venture capital. HiLabs has appointed Robert L. Renzi as Chief Growth Officer to lead its growth strategy and enhance partnerships with health plans.

The University of Sydney has developed PROTEUS, an AI system for molecule evolution in mammal cells. Modella AI partners with AstraZeneca for AI-driven cancer clinical development. Veeda Lifesciences collaborates with Mango Sciences to integrate AI in clinical trials. Caris Life Sciences validates its blood-based assay for cancer detection.

Ipsos has introduced the GLP-1 PersonaBot, an AI tool aimed at providing insights into the consumer obesity treatment market. This tool allows companies to interact with AI personas for real-time data to guide R&D and marketing strategies. Experts from Navitas Life Sciences discuss the transformative impact of AI, ML, RWE, DCTs, and master protocols on clinical research, focusing on improved efficiency and patient access.

Lifeforce and Toku have partnered to integrate AI retinal scans into health assessments. Viome Life Sciences has teamed up with Microsoft to enhance preventive healthcare through RNA data integration. i-Function® and Lunavi launched the LASSI-D™ platform for early cognitive decline detection.